SyntheX
Company

Last deal

$5.18M

Amount

Venture - Series Unknown

Stage

29.12.2023

Date

3

all rounds

$11.58M

Total amount

date founded

Financing round

General

About Company
SyntheX disrupts intracellular protein-protein interactions using synthetic biology for oncology drug selection.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2016

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company's platform, which uses genetically engineered circuits and proprietary DNA-encoded libraries of peptides and macrocycles, allows for unbiased discovery of compounds with novel modes of action that can engage targets in competitive or allosteric ways. SyntheX has developed ToRPPIDO and ToRNeDO to discover disruptors of protein-protein interactions and functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase, respectively. The company's lead programs focus on oncology, with targets selected based on synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.
Contacts

Contact Email

Phone number

Social url

Legal Names

Legal name

SyntheX,Inc.
Similar Companies
1000
Dyve Biosciences

Dyve Biosciences

Dyve develops novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Thousand Oaks, CA, USA

total rounds

5

total raised

$9.76M
AbCellera Biologics

AbCellera Biologics

AbCellera is a Vancouver-based company focused on antibody discovery and immune profiling.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Vancouver, BC, Canada

total rounds

12

total raised

$888.94M

count Of Investments

2
Demuris

Demuris

Demuris is a drug discovery firm that aims to revolutionize the natural product drug pipeline.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Newcastle upon Tyne, UK
Curve Therapeutics

Curve Therapeutics

Curve develops an innovative screening platform for drug discovery.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

Southampton, UK

total rounds

1

total raised

$30.85M

Financials

Funding Rounds
5
3

Number of Funding Rounds

$11.58M

Money Raised

Their latest funding was raised on 29.12.2023. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
29.12.2023
$5.18M
27.07.2022
2
Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Health Care, Manufacturing

Location

New York, NY, USA

total rounds

5

total raised

$23.58B

count Of Investments

77

count Of Exists

1
Co-Investors
Investors
6
6

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Convertible Note
Yes
Corporate Round
Yes
Convertible Note, Seed
IndieBio

IndieBio

IndieBio is a biotechnology and life science startup accelerator that focuses on solving global problems using biology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

1

total raised

$25M

count Of Investments

493

count Of Exists

7
Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Health Care, Manufacturing

Location

New York, NY, USA

total rounds

5

total raised

$23.58B

count Of Investments

77

count Of Exists

1
SOSV

SOSV

SOSV is a global venture capital firm that supports early-stage startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital

Location

Princeton, NJ, USA

count Of Investments

2641

count Of Exists

91
Arvind Gupta

Arvind Gupta

Arvind Gupta co-leads Mayfield’s Engineering Biology practice. He was the first investor in breakout bio companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite and Memphis Meats. As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years, defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value. Under his leadership, IndieBio expanded to New York and grew to fifteen investment professionals with a world class adjunct partner board. He is now Venture Advisor at IndieBio. Arvind is the author of Decoding the World: A Roadmap for the Questioner, published by Twelve Books, a division of the Hachette Publishing Group. He was honored with the F50 Global Award for Impact in HealthTech Innovation. He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech. His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China. Arvind has been a guest lecturer at UCSF, MIT and Harvard and is a judge at the annual BIO conference startup stadium. Prior to founding IndieBio, Arvind was Design Director at IDEO in Shanghai where he earned numerous international design awards and presented his work at the San Francisco Museum of Modern Art. Arvind received his B.S. in Genetic Engineering from UCSB. He holds 8 patents. Arvind is married to an Icelander and has two daughters.

current job

SOSV
SOSV

organization founded

1

People

Founders
2
Charly Chahwan
Charly Chahwan

Charly Chahwan

Charly Chahwan is the Co Founder, CSO at SyntheX.

current job

SyntheX
SyntheX

organization founded

1

Charly Chahwan

Maria Soloveychik
Maria Soloveychik

Maria Soloveychik

Maria Soloveychik and Charly Chahwan are working on curing untreatable cancer. They are disrupting the drug discovery cycle which typically takes $10m to $15m and upto 6 years. They have created compounds that have similar efficacy as other drugs and they were able to get to that stage in 2 months at the cost of $20,000 … I am going to let that sit with you. If that is not disruptive I am not sure what is. Maria Soloveychik is the CEO and co-founder of SyntheX Labs, a biotech company developing peptide therapeutics for cancer and other rare diseases. SyntheX labs was part of IndieBio batch #3 in 2016. They have successfully raised seed capital to move their vision forward. It was exciting to talk to Maria, she embodies everything that is inspiring about a founder.

current job

SyntheX
SyntheX

organization founded

1

Maria Soloveychik

Employee Profiles
3

Tri Luong

Head of Finance and Operations

Maria Soloveychik

Maria Soloveychik

Chief Executive Officer & Co-Founder

Charly Chahwan

Charly Chahwan

Co Founder & Chief Scientific Officer

Activity

Recent News
0